Efficacy and effects of Panitumumab

Several bowel cancer studies have shown that panitumumab is effective in extending the lives or slowing the progression of the disease in patients with "wild-type" RAS tumors that have spread. These studies showed that panitumumab was effective both when used alone and with the standard chemotherapy regimens FOLFOX (a combination of fluorouracil with leucovorin and the cancer drug oxaliplatin) or FOLFIRI (a combination of fluorouracil with leucovorin and a different cancer drug, irinotecan).

In a study of previously untreated patients, patients who received panitumumab plus FOLFOX lived an average of 10.1 months without their disease worsening, compared with an average of 7.9 months for those who received FOLFOX; About 59% of patients who received panitumumab plus FOLFIRI experienced a reduction in their cancer symptoms, and patients lived an average of 11.2 months without their disease worsening. In one study, patients with wild-type tumors who received panitumumab alone were free of disease progression for an average of 16 weeks, while patients who did not receive panitumumab and received only supportive care were free of disease progression for an average of 8 weeks. The study involved patients with wild-type or mutant RAS whose disease progressed despite treatment including fluoropyrimidine, oxaliplatin and irinotecan. The benefit was later confirmed to be limited to patients with wild-type RAS tumors.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.